Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIa trial of rhPDGF-BB gel for deep second-degree burn wounds
ChiCTR2600121373Phase 3Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of becaplermin in burn injury and deep second-degree burn (3 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Time to complete healing. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
becaplermin
03
Conditions
burn injurydeep second-degree burn
Beyond the preview
Go deeper on ChiCTR2600121373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121373.